All Stories

  1. Phase 1/1b Studies of UCB0599 , an Oral Inhibitor of α‐Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease

    Article • Movement Disorders, August 2022, Wiley

    Dr Laurent Detalle

  2. Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

    Article • August 2022, Springer Science + Business Media

    Dr Laurent Detalle

  3. Zilucoplan in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV): A structured summary of a study protocol for a randomised controlled trial

    Article • Trials, November 2020, Springer Science + Business Media

    Dr Laurent Detalle

  4. Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial

    Article • The Lancet Respiratory Medicine, September 2020, Elsevier

    Dr Laurent Detalle

  5. Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures

    Article • Antimicrobial Agents and Chemotherapy, November 2019, ASM Journals

    Dr Laurent Detalle

  6. Delivery of ALX-0171 by inhalation greatly reduces respiratory syncytial virus disease in newborn lambs

    Article • mAbs, May 2018, Taylor & Francis

    Dr Laurent Detalle

  7. Nanobodies® † †Nanobody is a registered trademark of Ablynx NV. as inhaled biotherapeutics for lung diseases

    Article • Pharmacology & Therapeutics, January 2017, Elsevier

    Dr Laurent Detalle

  8. Translational Aspects in Drug Discovery

    Article • January 2017, Elsevier

    Dr Laurent Detalle

  9. Trivalency of a Nanobody Specific for the Human Respiratory Syncytial Virus Fusion Glycoprotein Drastically Enhances Virus Neutralization and Impacts Escape Mutant Selection

    Article • Antimicrobial Agents and Chemotherapy, August 2016, ASM Journals

    Dr José A Melero , Dr Laurent Detalle

  10. High Throughput Combinatorial Formatting of PcrV Nanobodies for Efficient Potency Improvement

    Article • Journal of Biological Chemistry, May 2016, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Laurent Detalle

  11. Kinetics of Respiratory Syncytial Virus (RSV) Memphis Strain 37 (M37) Infection in the Respiratory Tract of Newborn Lambs as an RSV Infection Model for Human Infants

    Article • PLoS ONE, December 2015, PLOS

    Dr Laurent Detalle

  12. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection

    Article • Antimicrobial Agents and Chemotherapy, October 2015, ASM Journals

    Prof. Ultan F Power, Dr Laurent Detalle

  13. Involvement of Fcα/μ Receptor in IgM Anti-Platelet, but Not Anti–Red Blood Cell Autoantibody Pathogenicity in Mice

    Article • The Journal of Immunology, September 2015, The American Association of Immunologists

    Dr Laurent Detalle

  14. Antibody-Independent Thrombocytopenia in Lactate Dehydrogenase-Elevating Virus-Infected Mice

    Article • Journal of Virology, August 2012, ASM Journals

    Dr Laurent Detalle

  15. ALX-0171 toxicity study in RSV-infected cotton rats: Safety and therapeutic potential

    Article • Toxicology Letters, June 2012, Elsevier

    Dr Laurent Detalle

  16. Characterization of the T-lymphocyte response elicited by mouse immunization with rat platelets

    Article • Experimental Hematology, June 2011, Elsevier

    Dr Laurent Detalle

  17. Immunoglobulin M antiplatelet autoantibodies from mice immunized with rat platelets induce thrombocytopenia and platelet function impairment

    Article • Experimental Biology and Medicine, December 2010, SAGE Publications

    Dr Laurent Detalle

  18. Two-Step Mechanism of Virus-induced Autoimmune Hemolytic Anemia

    Article • Annals of the New York Academy of Sciences, August 2007, Wiley

    Dr Laurent Detalle

  19. Enhancement of autoantibody pathogenicity by viral infections in mouse models of anemia and thrombocytopenia

    Article • Autoimmunity Reviews, April 2005, Elsevier

    Dr Laurent Detalle